Identifier |
20000330_nanos_disorderssynapsesympos_07 |
Title |
Drug Therapy in Myasthenia Gravis and Congenital Myasthenic Syndromes |
Creator |
Preston C. Calvert |
Affiliation |
Baltimore, MD |
Subject |
Myasthenia Gravis; Congenital Myasthenic Syndromes; Neuromuscular Junction; Congenital Myasthenic Syndromes; Pharmacologic Suppression |
Description |
While surgical removal of the thymus gland or a thymoma is often part of the therapy of myasthenia gravis (MG), the mainstay of management for ocular MG remains drug therapy. While not every patient with MG needs medical therapy, most patients benefit from it, and it must be carefully tailored to the individual patient's overall medical situation. For the congenital myasthenic syndromes (CMS) due to genetically-determined molecular defects in the neuromuscular junction (NMJ), drug therapy can produce important improvements in motor function and quality of life. |
Date |
1999-03-18 |
Language |
eng |
Format |
application/pdf |
Type |
Text |
Source |
2000 North American Neuro-Ophthalmology Society Annual Meeting |
Relation is Part of |
NANOS 2000: Disorders of the Synapse |
Collection |
Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu |
Publisher |
Spencer S. Eccles Health Sciences Library, University of Utah |
Holding Institution |
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416 |
Rights Management |
Copyright 2000. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
ARK |
ark:/87278/s64b66v5 |
Context URL |
The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/ |
Setname |
ehsl_novel_nam |
ID |
182350 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s64b66v5 |